| Name | Title | Contact Details |
|---|---|---|
Andreas Busch |
Chief Innovation Officer | Profile |
Five Prime Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of protein therapeutics that block cancer and inflammatory disease processes. The company`s product candidates include FP-1039/GSK3052230, a protein therapeutic is in PhaseIb clinical trials for trapping and neutralizing cancer-promoting fibroblast growth factors (FGFs) involved in cancer cell proliferation and new blood vessel formation; FPA008, an antibody that inhibits colony stimulating factor-1 receptor; and FPA144 is an antibody for inhibiting FGF receptor 2b, as well as to treat patients with gastric cancer and potentially other solid tumors. It has collaboration and license agreements with GlaxoSmithKline LLC, Glaxo Group Limited, GSK-HGS, Pfizer Inc., and UCB Pharma S.A. The company was founded in 2001 and is headquartered in South San Francisco, California.
Cajal Neuroscience is a drug discovery company focused on neurodegenerative disease.
Oncoceutics Pharmaceuticals Inc is a Pittsburgh, PA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Fastgen Corporation is a San Mateo, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Biovista is a Charlottesville, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.